S. 1355 · 118th Congress (2023–2025)
PASTEUR Act of 2023
This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions.
A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.
Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.
HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.
Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.
Show official title
A bill to establish a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
This is S. 1355’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
Expired
- Sponsor
- Sen. Michael F. Bennet (D-CO)
- Cosponsors
7 cosponsors
1 original · 6 later
3 R · 4 D
- Sen. Todd Young (R-IN)· Original · Apr 27, 2023
- Sen. Kirsten E. Gillibrand (D-NY)· Later · Jun 1, 2023
- Sen. John W. Hickenlooper (D-CO)· Later · Jun 1, 2023
- Sen. Mike Rounds (R-SD)· Later · Jun 1, 2023
- Sen. Richard Blumenthal (D-CT)· Later · Sep 5, 2023
- Sen. J. D. Vance (R-OH)· Later · Nov 2, 2023
- Sen. Cory A. Booker (D-NJ)· Later · Dec 13, 2023
- Policy area
- Health
- Subjects
- Administrative law and regulatory procedures
- Advanced technology and technological innovations
- Advisory bodies
- Appropriations
- Department of Health and Human Services
- Drug therapy
- Executive agency funding and structure
- Government information and archives
7 more
- Government studies and investigations
- Health information and medical records
- Infectious and parasitic diseases
- Medical research
- Prescription drugs
- Public contracts and procurement
- Research and development
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sources
- Congress.gov action
- Senate
Expired
Introduced → Referred to Senate Health, Education, Labor, and Pensions → No further action before the 118th Congress ended.
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in Senate |
Titles (3)
PASTEUR Act of 2023
Display title, Short title · Introduced in Senate
Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023
Short title · Introduced in Senate
A bill to establish a program to develop antimicrobial innovations targeting the most challenging pathogens and most threatening infections, and for other purposes.
Official title · Introduced in Senate